Online inquiry

IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10819MR)

This product GTTS-WQ10819MR is a type of mRNA modified with 5-Methoxy-UTP, which ecodes the monoclonal antibody that targets PD-L1; TGFBR2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001267706.2; NM_001024847.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126; 7048
UniProt ID Q9NZQ7; P37173
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ10819MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9870MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA K7153A
GTTS-WQ15061MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SSS-23
GTTS-WQ6718MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DS 1024
GTTS-WQ2678MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 785
GTTS-WQ15951MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ6598MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DC-1728001
GTTS-WQ11680MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ13684MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RC18
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW